♦ Osteolytic bone metastasis of breast cancer: 90 mg as a 2-hour infusion given over 3 to 4 weeks.

♦ Osteolytic bone lesions of multiple myeloma: 90 mg as a 4-hour infusion on a monthly cycle. Patients with marked Bence-Jones proteinuria and dehydration should be adequately hydrated before the infusion.

♦ Hypercalcemia of malignancy: For moderate hyper-calcemia (corrected serum calcium 12.0 to 13.5 mg/dL), 60 to 90 mg. Give the 60-mg dose as an initial, single-dose infusion over 4 hours; give the 90-mg dose as an initial single-dose infusion over 24 hours. For severe hypercal-cemia (corrected serum calcium >13.5 mg/dL), 90 mg given as an initial, single-agent infusion over 24 hours. For hypercalcemic patients who show complete or partial response initially, treatment may be repeated, using the initial dose; 7 days should elapse before retreatment.